Last reviewed · How we verify
DCV 3DAA
DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication.
DCV 3DAA is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus NS3/4A protease, NS5B polymerase, and NS5A protein to block viral replication. Used for Chronic hepatitis C virus infection (genotype 1-6).
At a glance
| Generic name | DCV 3DAA |
|---|---|
| Also known as | Daclatasvir 30 mg /Asunaprevir 200 mg /BMS-791325 75 mg fixed dose combination |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Direct-acting antiviral combination (protease inhibitor + polymerase inhibitor + NS5A inhibitor) |
| Target | HCV NS3/4A protease, NS5B polymerase, NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
This triple direct-acting antiviral (3DAA) regimen targets multiple steps of the hepatitis C virus lifecycle simultaneously. By combining protease, polymerase, and NS5A inhibitors, the combination achieves high barrier to resistance and broad genotype coverage, enabling high cure rates across diverse patient populations with chronic hepatitis C.
Approved indications
- Chronic hepatitis C virus infection (genotype 1-6)
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects (PHASE3)
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis (PHASE3)
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C (PHASE3)
- Study of Drug Combination on Pharmacokinetics in Healthy Volunteers (PHASE1)
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (PHASE1)
- Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325 (PHASE1)
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet (PHASE1)
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |